Social network
Media - Staying connected to our latest news and events
Media - Staying connected to our latest news and events

Media

Staying connected to our latest news and events

Tools content (print, share, increase/decrease text size):

 

    Middle area:

    Press releases 2013

    Press releases are intended for journalists, analysts and investors.

    Genzyme Receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) Application

    December 30, 2013

    Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program

    December 19, 2013

    Merial Receives EMA approval for Broadline™ for Broad Spectrum Parasite Treatment and Prevention in Cats

    December 12, 2013

    FDA Grants Priority Review for Genzyme’s Cerdelga™ (eliglustat), an Investigational Oral Therapy for Gaucher Disease

    December 11, 2013

    New Data Support Flexibility in Timing of Administration for Sanofi’s Lyxumia®

    December 05, 2013

    Sanofi Announces New Phase 3 Results for Investigational New Insulin U300

    December 03, 2013

    Sanofi and Regeneron’s Dupilumab Named "Clinical Advance of the Year" by Scrip Intelligence

    November 25, 2013

    Sanofi Pasteur commends GAVI Alliance for Supporting the Introduction of Inactivated Polio Vaccine in World’s Poorest Countries

    November 22, 2013

    Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial

    November 22, 2013

    Sanofi Discontinues Clinical Development of Investigational JAK2 Agent Fedratinib (SAR302503)

    November 18, 2013

    Sanofi successfully prices EUR 1 billion bond issue

    November 07, 2013

    Sanofi and the Institut Pasteur Reward Four International Scientists for their Innovative Research in Life Sciences

    November 05, 2013

    Q3 2013 Marks the End of the Patent Cliff Period

    October 30, 2013

    Sanofi Launches “Action 2013”, a Worldwide Employee Stock Purchase Plan

    October 29, 2013

    Sanofi Pasteur Announces Vaccine Discovery Collaboration with the Bill & Melinda Gates Foundation

    October 29, 2013

    Sanofi Celebrates 50th Anniversary of Elysée Treaty

    October 21, 2013

    Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction

    October 16, 2013

    Sanofi Hosts French President François Hollande at Facility in South Africa

    October 15, 2013

    FDA Approves Sanofi’s Nasacort® Allergy 24HR for Over-the-Counter Use

    October 11, 2013

    Aubagio® Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study

    October 03, 2013

    Sanofi and Aviesan Renew their Agreement to Accelerate Research in France

    September 27, 2013

    Sanofi strengthens its presence in Algeria

    September 26, 2013

    Data Show Sanofi’s Lyxumia® Added to Basal Insulin Lowered Blood Sugar Especially when Fasting Plasma Glucose was Controlled

    September 24, 2013

    U.S. FDA Approves Merial’s NexGard™ (afoxolaner) Chewables for Treatment and Prevention of Fleas and Ticks in Dogs

    September 24, 2013

    Sanofi’s CSR Achievements Recognized by Two Global Indices

    September 19, 2013

    European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)

    September 17, 2013

    Sanofi Re-Introduces Rolaids® in the United States

    September 16, 2013

    Sanofi Provides Update on Lixisenatide New Drug Application in U.S.

    September 12, 2013

    Menomune® Is the First Quadrivalent Meningococcal Vaccine Prequalified by the WHO

    September 03, 2013

    European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)

    August 30, 2013

    Sanofi successfully prices EUR 1 billion bond issue

    August 29, 2013

    Sanofi Pasteur’s Fluzone High-Dose Vaccine Significantly More Effective Than Standard Dose Fluzone Vaccine in Preventing Influenza in Adults 65 Years of Age and Older

    August 26, 2013

    Sanofi Pasteur Initiates Phase III Study of Investigational Clostridium Difficile Vaccine

    August 05, 2013

    Online Availability of Sanofi Group’s Half-Year Financial Report for 2013

    August 02, 2013

    Q2 2013: Last Quarter with Significant Negative Impact from the Patent Cliff

    August 01, 2013

    FDA Advisory Committee Recommends Approval of Sanofi’s Nasacort® AQ Nasal Spray for Over-the-Counter Use

    July 31, 2013

    Sanofi Appoints Carsten Hellmann and David Meeker to the Executive Committee

    July 31, 2013

    Genzyme Receives Positive CHMP Opinion for LEMTRADA™ (alemtuzumab) in Europe

    June 28, 2013

    Lyxumia® is first diabetes therapy of its class approved in Japan for use in combination with basal insulin

    June 28, 2013

    Sanofi Expands Collaboration with GDF SUEZ to Reduce its Global Energy Consumption

    June 24, 2013

    Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300

    June 22, 2013

    Curie-Cancer and Sanofi cooperate in research on ovarian cancer

    June 19, 2013

    Sanofi to present new clinical data, including results from the investigational new insulin U300, at the American Diabetes Association 73rd Scientific Sessions

    June 18, 2013

    New Four-Strain Influenza Vaccine from Sanofi Pasteur Now Licensed By FDA for Broad Age Range of Children and Adults

    June 10, 2013

    ORIGIN Results on Lantus® Cardiovascular Safety Integrated Into European Union Product Label

    June 05, 2013

    Sanofi Provides Update on Phase 3 Studies of Two Investigational Compounds

    June 03, 2013

    Sanofi appoints David Loew, Senior Vice President, Commercial Operations, Europe

    May 23, 2013

    Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine

    May 21, 2013

    Sanofi announces the next steps of its Research site in Toulouse, France

    May 17, 2013

    Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis

    May 17, 2013

    Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)

    May 15, 2013

    Combined General Shareholder Meeting of May 3, 2013

    May 03, 2013

    Q1 2013 business EPS impacted by exclusivity losses in prior year. Growth platforms sales increased 8.6%

    May 02, 2013

    Sanofi appoints two new Members to the Executive Committee to lead the new Commercial Organization

    May 02, 2013

    Sanofi and DNDi celebrate six years of collaboration in fighting malaria by distributing 200 million treatments of ASAQ

    April 25, 2013

    Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study

    April 25, 2013

    Sanofi Pasteur to Provide 1.7 Billion Doses of Oral Polio Vaccine from 2013 to 2017 for Polio Eradication

    April 24, 2013

    Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe

    April 22, 2013

    Sanofi reinforces its presence in Morocco

    April 17, 2013

    Sanofi strengthens its French-German partnership on the occasion the French-German Week for Science and Alumni

    April 15, 2013

    Sanofi and PATH announce the Launch of Large-scale Production of Semisynthetic Artemisinin against Malaria

    April 11, 2013

    Sanofi Pasteur’s New Quadrivalent Influenza Vaccine Accepted for Review for European Approval

    April 11, 2013

    Sanofi successfully prices USD 1.5 billion bond issue

    April 04, 2013

    Sanofi to Invest USD 75 million in a New Manufacturing Facility in Vietnam

    March 29, 2013

    Sanofi signs collaboration agreement with Schneider Electric to accelerate its energy efficiency program on its industrial sites

    March 28, 2013

    Sanofi and Transgene Announce Innovative Long-Term Collaboration for the Production of Immunotherapy Treatments

    March 25, 2013

    Genzyme Receives Positive CHMP Opinion in the European Union for Once-daily, Oral AUBAGIO® to Treat Relapsing-Remitting Multiple Sclerosis

    March 22, 2013

    Effect of Genzyme’s LEMTRADA Maintained in Patients Beyond Two-Year Pivotal MS Studies

    March 21, 2013

    Genzyme’s Multiple Sclerosis Franchise Featured at AAN

    March 13, 2013

    Filing of the 2012 U.S. Form 20-F and French “Document de Référence" containing the Annual Financial Report

    March 08, 2013

    Composition of the Board of Directors of Sanofi

    March 05, 2013

    Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab

    March 02, 2013

    Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS)

    February 27, 2013

    European Medicines Agency Recommends Approval of Hexyon/Hexacima 6-in-1 Pediatric Vaccine

    February 22, 2013

    Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

    February 19, 2013

    Genzyme Announces Positive New Data from Two Phase 3 Studies for Oral Eliglustat Tartrate for Gaucher Disease

    February 15, 2013

    The Sanofi Espoir Foundation and the Union for International Cancer Control are extending their My Child Matters partnership for another three years

    February 14, 2013

    Sanofi delivers solid 2012 results despite patent expirations

    February 07, 2013

    ZALTRAP® (aflibercept) Approved in the EU for Patients with Previously Treated Metastatic Colorectal Cancer

    February 05, 2013

    Once-Daily Lyxumia® (lixisenatide) Approved for Treatment of Type 2 Diabetes in Europe

    February 04, 2013

    Genzyme and Isis Announce FDA Approval of KYNAMRO™ (mipomersen sodium) Injection for the Treatment of Homozygous Familial Hypercholesterolemia

    January 29, 2013

    Sanofi Announces Auvi-Q™, the First and Only Voice-Guided Epinephrine Auto-Injector, is Now Available in the U.S.

    January 28, 2013

    Genzyme’s LEMTRADA™ (alemtuzumab) Application for MS Accepted for Review by the FDA

    January 28, 2013

    Sanofi Provides an Update on its Research & Development Pipeline

    January 08, 2013

    Sanofi’s Chattem Acquires Over-the-Counter Antacid Rolaids®

    January 07, 2013

    Sanofi Appoints Dr. Gary J. Nabel as Chairman of the Strategic Development and Scientific Advisory Council

    January 07, 2013

    Right area:

    Search

    Search

     
       

    Filter by date

     
     
     
     
     

    © Sanofi 2004-2016 - All rights reserved - Update: March 12, 2015

    • Site complies with W3C WCAG 2.0 (new window, in english)